# Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

> **NCT07564453** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 101 (estimated)

## Conditions studied

- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

## Interventions

- **BIOLOGICAL:** Blinatumomab
- **DRUG:** Induction Chemotherapy
- **DRUG:** Hyper-CVAD
- **PROCEDURE:** Allogeneic hematopoietic stem cell transplantation
- **BIOLOGICAL:** CAR-T cell therapy

## Key facts

- **NCT ID:** NCT07564453
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 101 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07564453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07564453, "Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07564453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*